Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / SCYX - DEADLINE ALERT for SCYX LICY and FMC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders | Benzinga


SCYX - DEADLINE ALERT for SCYX LICY and FMC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders | Benzinga

  • LOS ANGELES, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

    Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com.

    SCYNEXIS, Inc. (NASDAQ:SCYX)
    Class Period: March 31, 2023 – September 22, 2023
    Lead Plaintiff Deadline: January 8, 2024

    The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the equipment used to manufacture ibrexafungerp was also used to manufacture a non-antibacterial beta-lactam drug substance, presenting a risk of cross-contamination; (2) that the Company did not have effective internal controls and procedures, as well as adequate internal oversight policies to ensure that its vendor complied with current Good Manufacturing Practices (cGMP); (3) that, due to the substantial risk of cross-contamination, Scynexis was reasonably likely to recall its ibrexafungerp tablets and halt its clinical studies; and (4) as a result of the foregoing, ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: SCYNEXIS Inc.
    Stock Symbol: SCYX
    Market: NASDAQ
    Website: scynexis.com

    Menu

    SCYX SCYX Quote SCYX Short SCYX News SCYX Articles SCYX Message Board
    Get SCYX Alerts

    News, Short Squeeze, Breakout and More Instantly...